Search Results
Jan 29, 2026, 16:05 ET BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes").
More news about: BioMarin Pharmaceutical Inc.
Jan 26, 2026, 07:45 ET BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the
More news about: BioMarin Pharmaceutical Inc.
Jan 12, 2026, 16:05 ET BioMarin Appoints Arpit Davé Chief Digital and Information Officer
SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to
More news about: BioMarin Pharmaceutical Inc.
Jan 09, 2026, 07:57 ET Veeva e BioMarin formam uma parceria estratégica de longo prazo
Veeva Systems (NYSE: VEEV) e a BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) anunciaram um acordo empresarial de longo prazo que se baseia em seu relacionamento de longa data.
More news about: Veeva Systems
Jan 09, 2026, 07:50 ET Veeva y BioMarin forman alianza estratégica a largo plazo
Veeva Systems (NYSE: VEEV) y BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) anunciaron un acuerdo empresarial a largo plazo que consolida su longeva relación.
More news about: Veeva Systems
Jan 09, 2026, 06:07 ET Veeva und BioMarin schließen langfristige strategische Partnerschaft
Veeva Systems (NYSE: VEEV) und BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) gaben eine langfristige Unternehmensvereinbarung bekannt, die auf ihrer langjährigen Beziehung aufbaut.
More news about: Veeva Systems
Jan 09, 2026, 06:01 ET Veeva et BioMarin forment un partenariat stratégique à long terme
Veeva Systems (NYSE : VEEV) et BioMarin Pharmaceutical Inc. (NASDAQ : BMRN) ont annoncé la conclusion d'un accord d'entreprise à long terme dans le prolongement de leur relation de longue date.
More news about: Veeva Systems
Jan 08, 2026, 16:05 ET BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 44th Annual J.P. Morgan Conference on Monday,
More news about: BioMarin Pharmaceutical Inc.
Jan 08, 2026, 11:31 ET Veeva y BioMarin forman una alianza estratégica a largo plazo
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) anunciaron un acuerdo empresarial a largo plazo que se basa en su relación de larga data.
More news about: Veeva Systems
Jan 08, 2026, 08:30 ET Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship.
More news about: Veeva Systems
Jan 08, 2026, 08:30 ET Veeva and BioMarin Form Long-Term Strategic Partnership
Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship.
More news about: Veeva Systems
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share
More news about: BioMarin Pharmaceutical Inc.
Nov 11, 2025, 09:00 ET BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
SAN RAFAEL, Calif., Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London,
More news about: BioMarin Pharmaceutical Inc.
Oct 29, 2025, 09:00 ET FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
SAN RAFAEL, Calif., Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ® (pegvaliase-pqpz)
More news about: BioMarin Pharmaceutical Inc.
Oct 27, 2025, 16:03 ET BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
SAN RAFAEL, Calif., Oct. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025.
More news about: BioMarin Pharmaceutical Inc.
Oct 22, 2025, 16:05 ET BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, October
More news about: BioMarin Pharmaceutical Inc.
Oct 01, 2025, 11:04 ET BioMarin apresenta novos dados que reforçam sua liderança em saúde óssea na reunião anual da Sociedade Americana de Pesquisa Óssea e Mineral
SÃO PAULO, 1 de outubro de 2025 /PRNewswire/ -- A BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) anunciou que 14 novos estudos foram apresentados na Reunião Anual de 2025 da Sociedade Americana de Pesquisa Óssea e Mineral (ASBMR), realizada em Seattle,
More news about: BioMarin
Sep 26, 2025, 15:50 ET BioMarin anuncia dados positivos de fase 3 para PALYNZIQ® (pegvaliase-pqpz) em adolescentes com fenilcetonúria no 15º Congresso Internacional de Erros Inatos do Metabolismo
SÃO PAULO, 26 de setembro de 2025 /PRNewswire/ -- A BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) anunciou novos dados que caracterizam a eficácia e o perfil da segurança do PALYNZIQ® (pegvaliase-pqpz) para o tratamento de adolescentes com fenilcetonúria
More news about: BioMarin